Acrux patent triggers milestone payment
Friday, 19 November, 2004
Acrux (ASX:ACR) has received a US$250,000 milestone payment from its partner Vivus triggered by the granting of a US patent extending the coverage of its proprietary transdermal drug delivery system.
The patent provides protection for transdermal drug delivery systems consisting of an effective amount of a therapeutic drug, a dermal penetration enhancer and a volatile liquid, with an area of application that becomes touch-dry within 3 minutes of administration.
CEO Igor Gonda said the patent claims provided strategic protection for the product compared to other transdermal drug delivery systems including patches and gels. Acrux has similar patents pending in other international markets.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
